What question did this study set out to answer?

The study investigates the trends and factors influencing end-of-life immunotherapy initiation among patients with metastatic head and neck squamous cell carcinoma.

May 29, 2026Journal of Clinical Oncology

Trends in end-of-life immunotherapy use in metastatic head and neck squamous cell carcinoma: A National Cancer Database analysis.

View Full Paper

Ask AI

Bookmark

Authors

RSRonit SethiIcahn School of Medicine at Mount Sinai SASeungjun AhnIcahn School of Medicine at Mount Sinai OFOlivia FirstIcahn School of Medicine at Mount Sinai

Discussion

Member takes

Implication

Retrospective cohort study examines EOL immunotherapy use in metastatic head and neck cancer, highlighting clinical and demographic factors.

Key Points

The study investigates the trends and factors influencing end-of-life immunotherapy initiation among patients with metastatic head and neck squamous cell carcinoma.
Identified patients with metastatic head and neck squamous cell carcinoma receiving immunotherapy from 2016-2022 in the National Cancer Database.
Defined end-of-life immunotherapy as initiation within one month of death and conducted logistic regression analysis to identify associated factors.
Performed two-sample t-tests and chi-squared tests for comparison between EOL and non-EOL groups.
Among 8,806 patients, the rate of EOL immunotherapy increased from 17.7% in 2016 to 40.9% in 2022.
EOL immunotherapy was initiated in 6.7%, 13.0%, and 16.4% of patients at 1-, 2-, and 3-month EOL thresholds by 2021, respectively.
Predictors for EOL initiation included female sex (OR=2.09) and high metastatic burden (OR=8.77), while academic settings were protective (OR=0.60).

Cite This Study

Sethi et al. (2026) studied this question.

synapsesocial.com/papers/6a192e79fab5b468c44179ca https://doi.org/10.1200/jco.2026.44.16_suppl.6035

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study examines EOL immunotherapy use in metastatic head and neck cancer, highlighting clinical and demographic factors.

Trends in end-of-life immunotherapy use in metastatic head and neck squamous cell carcinoma: A National Cancer Database analysis.

Discussion

Member takes

Implication

Key Points

Cite This Study

Trends in end-of-life immunotherapy use in metastatic head and neck squamous cell carcinoma: A National Cancer Database analysis.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider